Global Overactive Bladder (OAB) Therapeutics Industry
NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Overactive Bladder (OAB) Therapeutics Industry
http://www.reportlinker.com/p0611038/Global-Overactive-Bladder-OAB-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_
This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 34 companies including many key and niche players such as Allergan, Inc., Antares Pharma, Inc., Apogepha Arzneimittel GmbH, Astellas Pharma, Inc., Auxilium Pharmaceuticals, Inc., Kissei Pharmaceuticals Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pfizer, Inc., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
Outlook 4
Current & Future Analysis 4
Underdiagnosis - A Key Market Deterrent 4
Increasing Awareness- A Key to Success 5
Reaching Out to Urologists - A Key Strategy 5
Improved OAB Medications to Drive Growth 5
Ageing Population Reflect Significant market Opportunity 6
Table 1: Ageing (65+) Demographics as % of Total Population
by Country (2000, 2010, 2025) (includes corresponding
Graph/Chart) 6
Table 2: Prevalence (%) of Overactive Bladder Symptoms by Age
(includes corresponding Graph/Chart) 7
Meager OAB Developmental Pipeline Deters Growth Prospects 7
Generics Stalls Revenues 7
3. COMPETITION 8
The Branded Drugs Landscape 8
Table 3: Sales of Major Overactive Bladder Drugs (2009) (In
US$ Million) (includes corresponding Graph/Chart) 8
Review of Select Available Drugs 9
Detrol and Detrol LA (Tolterodine tartrate) 9
VESIcare® (solifenacin succinate) 9
SANCTURA® (trospium chloride) 9
Toviaz® (fesoterodine fumarate) 9
Enablex® (Darifenacin) 9
Ditropan and Ditropan XL (Oxybutynin chloride) 9
Oxytrol (Oxybutynin Patch) 10
The OAB Brand Matrix 10
4. URINARY INCONTINENCE - AN INSIGHT 11
How Does Normal Urinary Bladder Function? 11
What is Urinary Incontinence? 11
Male Incontinence 11
Women More Prone to Incontinency than Men 12
Incontinence Among Children 12
Types of Urinary Incontinence 12
Stress Incontinence 12
Urge Incontinence 13
Functional Incontinence 13
Overflow Incontinence 13
Mixed Incontinence 14
Reflex Incontinence 14
Transient Incontinence 14
Traumatic Incontinence 14
5. OVERACTIVE BLADDER 15
Definition 15
Types 15
By Incontinence 15
Overactive Bladder Dry 15
Overactive Bladder Wet 15
By Symptomatic Causes 15
Neurogenic OAB 15
Idiopathic OAB 16
Etiology 16
Symptoms 16
Impact of Overactive Bladder on Quality of Life 16
Diagnosis 17
Measurement of Postvoid Residual Urine 17
Cystoscopy 17
Uroflowmetry 18
Cystometry 18
Electromyography 18
Video Urodynamics 18
Treatment Options 18
Behavioral Remedies 18
Pharmacotherapy 19
Anticholinergic agents 19
Other Therapeutic Approaches 19
Device Therapy 19
Device Therapies in Men 19
Device and Minimally-Invasive Therapies in Women 20
Neuromodulation 20
Vaginal Devices 20
Collagen Injections 20
Retropubic Suspension 20
Sling Procedure 20
Midurethral Slings 21
Dietary Changes and Alternative Medicines 21
6. PRODUCT LAUNCHES/INTRODUCTIONS 22
Dr. Reddy's Laboratories Launches Bispec 22
Watson Pharmaceuticals Introduces GELNIQUE™ (oxybutynin
chloride) Gel 10% 22
Pfizer Launches TOVIAZ® 22
7. RECENT INDUSTRY ACTIVITY 24
Warner Chilcott Purchases US Rights of Enablex from Novartis 24
Serenity Pharmaceuticals and Allergan Enter Into Agreement 24
Astellas Pharma Applies for Approval of YM178 in Japan 24
Kyorin Pharmaceutical and Ono Pharmaceutical Independently
File NDA 24
Endo Pharmaceuticals Purchases Indevus Pharmaceuticals 25
Allergan Signs Co-promotion Agreement with Quintiles
Transnational 25
P&G Inks Agreement with Warner Chilcott 25
Astellas Pharma to Introduce Vesicare in China 26
Kyorin Pharmaceutical Inks Licensing Agreement with Eisai 26
Astellas Pharma Unveils Expansion Plans in India 26
Speciality European Pharma Obtains Distribution Rights to
Regurin and Regurin XL 27
Toray and Taiho Pharmaceutical Enter into Alliance 27
Astellas Pharma Files Patent Infringement Lawsuit against Teva
Pharmaceutical 27
Indevus Pharmaceuticals Inks License Agreement with Allergan 27
Asahi Kasei Obtains Intellectual Property Rights of Flivas
from Roche Diagnostics 28
8. FOCUS ON SELECT GLOBAL PLAYERS 29
Allergan, Inc. (US) 29
Antares Pharma, Inc. (US) 29
Apogepha Arzneimittel GmbH (Germany) 29
Astellas Pharma, Inc. (Japan) 30
Auxilium Pharmaceuticals, Inc. (US) 30
Kissei Pharmaceuticals Co., Ltd. (Japan) 30
KYORIN Pharmaceutical Co., Ltd. (Japan) 30
Novartis AG (Switzerland) 31
Ono Pharmaceutical Co., Ltd. (Japan) 31
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (USA) 31
Pfizer, Inc. (US) 32
SALVAT Biotech (Spain) 32
Sepracor Pharmaceuticals, Inc. (Canada) 32
Watson Pharmaceuticals, Inc. (US) 33
9. GLOBAL MARKET PERSPECTIVE 34
Table 4: World Recent Past, Current & Future Market Analysis
for Overactive Bladder Therapeutics by Country/Geographic
Region - US, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Revenues in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) 34
Table 5: World Historic Review for Overactive Bladder
Therapeutics by Country/Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Consumption in Thousand Metric Tons for Years 2003 through
2008 (includes corresponding Graph/Chart) 35
Table 6: World 15-Year Perspective for Overactive Bladder
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US and Rest of World Markets for Years 2003,
2010 & 2017 (includes corresponding Graph/Chart) 36
10. THE UNITED STATES 37
A.Market Analysis 37
Overview 37
Competition 37
Table 7: US Market for Overactive Bladder Therapeutics
(2009): Percentage Share Breakdown by Drugs- Detrol/Detrol
LA, Vesicare, Enablex, Generic Oxybutynin,
Sanctura/Sanctura XR and Others (includes corresponding
Graph/Chart) 37
Table 8: US Market for OAB Drugs: Prescription Share for
Oral and Transdermal Medications 38
Patent Expiry of Select Overactive Bladder Drugs 38
Strategic Corporate Developments 38
Key Player Review 40
B.Market Analytics 42
Table 9: The United States Recent Past, Current & Future
Market Analysis for Overactive Bladder Therapeutics with
Annual Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 42
Table 10: The United States Historic Review for Overactive
Bladder Therapeutics with Annual Revenues in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) 43
11. JAPAN 44
A.Market Analysis 44
Strategic Corporate Developments 44
Key Player Review 44
B.Market Analytics 46
Table 11: Japanese Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 46
Table 12: Japanese Historic Review for Overactive Bladder
Therapeutics with Annual Revenues in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 47
12. EUROPE 48
A.Market Analysis 48
Key Player Review 48
B.Market Analytics 49
Table 13: European Past, Current & Future Market Analysis
for Overactive Bladder Therapeutics by Country/Geographic
Region - France, Germany, Italy, UK, and Rest of Europe
Markets Independently Analyzed with Annual Revenues in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 49
Table 14: European Historic Review for Overactive Bladder
Therapeutics by Country/Geographic Region - France, Germany,
Italy, UK, and Rest of Europe Markets Independently Analyzed
with Annual Revenues in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 50
Table 15: European 15-Year Perspective for Overactive
Bladder Therapeutics by Country/Geographic Region -
Percentage Breakdown of Dollar Sales for France, Germany,
Italy, UK, and Rest of Europe Markets for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 51
12a. FRANCE 52
Market Analysis 52
Table 16: French Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 52
Table 17: French Historic Review for Overactive Bladder
Therapeutics with Annual Revenues in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 52
12b. GERMANY 53
Market Analysis 53
Table 18: German Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 53
Table 19: German Historic Review for Overactive Bladder
Therapeutics with Annual Revenues in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 53
12c. ITALY 54
Market Analysis 54
Table 20: Italian Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 54
Table 21: Italian Historic Review for Overactive Bladder
Therapeutics with Annual Revenues in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 54
12d. THE UNITED KINGDOM 55
Market Analysis 55
Table 22: The UK Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 55
Table 23: The UK Historic Review for Overactive Bladder
Therapeutics with Annual Revenues in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) 55
12e. REST OF EUROPE 56
Market Analysis 56
Table 24: Rest of Europe Recent Past, Current & Future
Market Analysis for Overactive Bladder Therapeutics with
Annual Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 56
Table 25: Rest of Europe Historic Review for Overactive
Bladder Therapeutics with Annual Revenues in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) 57
13. REST OF WORLD 58
A.Market Analysis 58
Strategic Corporate Developments 58
B.Market Analytics 59
Table 26: Rest of World Recent Past, Current & Future Market
Analysis for Overactive Bladder Therapeutics with Annual
Revenues in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 59
Table 27: Rest of World Historic Review for Overactive
Bladder Therapeutics with Annual Revenues in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) 60
COMPETITIVE LANDSCAPE
Total Companies Profiled: 34 (including Divisions/Subsidiaries - 39)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 16
Canada 2
Japan 9
Europe 10
Germany 3
The United Kingdom 2
Italy 2
Spain 1
Rest of Europe 2
Asia-Pacific (Excluding Japan) 2
------------------------------------------
To order this report:
Drug and Medication Industry: Global Overactive Bladder (OAB) Therapeutics Industry
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article